Geschmack ist vorhersagbar: Mit FlavorMiner. FlavorMiner heißt das Tool, das IPB-Chemiker und Partner aus Kolumbien jüngst entwickelt haben. Das Programm kann, basierend auf maschinellem Lernen (KI), anhand der…
Seit Februar 2021 bietet Wolfgang Brandt, ehemaliger Leiter der Arbeitsgruppe Computerchemie am IPB, sein Citizen Science-Projekt zur Pilzbestimmung an. Dafür hat er in regelmäßigen Abständen öffentliche Vorträge zur Vielfalt…
Hmedat, A.; Morejón, M.; Rivera, D.; Pantelić, N.; Wessjohann, L.; Kaluđerović, G. N.;In vitro anticancer studies of a small library of cyclic lipopeptides against the human cervix adenocarcinoma HeLa cellsJ. Serb. Chem. Soc.89471-484(2024)DOI: 10.2298/jsc240109018h
Various cyclic lipopeptides (CLPs, 23 compounds) were tested for their antitumor potential against human cervix adenocarcinoma HeLa cells. From the fast screening (tested concentrations: 0.01 and 10 μM) compound 10 ((12S,6S,10S,13S)-6-((R)-sec-butyl)-7-(2-(dodecylamino)-2-oxoethyl)-13-isopropyl- 82-nitro-2,5,12,15-tetraoxo-4,7,11,14-tetraaza-1(1,2)-pyrrolidina-8(1,4)-benzenacyclopentadecaphane- 10-carboxamide) was identified as active against HeLa cell line. The MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide and CV (crystal violet) assays revealed at least five times higher cytotoxic potential of 10 (IC50 = 12.3±1.8 μM, MTT; 9.4±1.5 μM; CV) in comparison to control drug natural occurring CLP surfactin (IC50 = 64.9±0.8 μM, MTT; 76.2±1.6 μM; CV). The cell cycle analysis performed by DAPI (4\',6-diamidino- 2-phenylindole) assay indicated the involvement of apoptosis in HeLa cell death upon treatment with 10, which was confirmed by apoptosis assay (annexin V/PI). Furthermore, during this process caspase activation could be detected (ApoStat assay, immunocytochemistry caspase-3 analysis). The flow cytometry analysis did not display induction of autophagy as a possible death mechanism in HeLa cells upon 10 treatment. The current findings could be used to design more effective CLPs based on 10 structure as potential anticancer agents.
Publikation
Eichhorn, T.; Đošić, M.; Dimić, D.; Morgan, I.; Milenković, D.; Rennert, R.; Amić, A.; Marković, Z.; Kaluđerović, G. N.; Dimitrić Marković, J.;Ru(II)‐nitrophenylhydrazine/chlorophenylhydrazine complexes: Nanoarchitectonics, biological evaluation and in silico studyEur. J. Inorg. Chem.27e202300683(2024)DOI: 10.1002/ejic.202300683
Ru(II)‐arene compounds are being investigated as anticancer agents due to the biocompatibility of ruthenium and their structural diversity. Two newly synthesized Ru(II) complexes, [RuCl(η6‐p‐cymene)(3‐DNPH)] (chlorido(η6‐p‐cymene)(3‐nitrophenylhydrazine‐k2N,N′)ruthenium(II)) (1) and [RuCl(η6‐p‐cymene)(3‐CNPH)] (chlorido(3‐chlorophenylhydrazine‐k2N,N′)(η6‐p‐cymene)ruthenium(II)) (2), are experimentally (IR, NMR) and theoretically (B3LYP/6‐31+G(d,p)(H,C,N,Cl)/LanL2DZ(Ru)) characterized. Experimental and theoretical values of 1H and 13C chemical shifts and position of the most intense vibrational bands showed high correlation coefficients and low mean absolute errors, proving the predicted structure and applicability of the selected level of theory. Cell viability studies performed on MDA‐MB‐468, BT‐474, and PC3 cells using MTT and CV assay indicated the activity of the second complex similar to the activity of cisplatin towards BT‐474 breast cancer cells. The spectrofluorimetric measurements of Bovine Serum Albumin showed the binding process‘s spontaneity of complexes and protein, with a binding energy of around −30 kJ mol−1. Detailed molecular docking analysis allowed the elucidation of the binding mechanism through specific intermolecular interactions. Both compounds showed a higher affinity towards BSA than naproxen and cisplatin. Molecular docking simulations proved the spontaneity of the complexes binding to DNA. Based on these promising results, further biological examinations of these compounds are advised.Graphical Abstract
The cytotoxicity, protein binding affinity, interactions
with DNA, spectral and structural features of two new Ru(II) compounds,
[RuCl(η6-p-cymene)(3-DNPH)] chlorido(η6-p-cymene)(3-nitrophenylhydrazine-k2N,N′)ruthenium(II) and [RuCl(η6-p-cymene)(3-CNPH)] chlorido(3-chlorophenylhydrazine-k2N,N′)(η6-p-cymene)ruthenium(II), are examined experimentally and theoretically.
Publikation
Morgan, I.; Rennert, R.; Berger, R.; Jelača, S.; Maksimović-Ivanić, D.; Dunđerović, D.; Mijatović, S.; Kaluđerović, G. N.; Wessjohann, L. A.;The impact of 9-azaglycophymine and phenylguanidine derivatives on the proliferation of various breast cancer cell lines in vitro and in vivoSci. Rep.1428126(2024)DOI: 10.1038/s41598-024-71624-8
Quinazolinones, particularly 9-azaglycophymines, and closely related derivatives and precursors were tested in vitro against various breast cancer cell lines representing the major types of breast tumors. Among the 49 compounds tested, azaglycophymine derivative 19 with an electron-withdrawing substituent demonstrated the most significant anti-proliferative effects, with IC50 values of around 4 µM. Extensive cell-based investigations revealed that compound 19 induced caspase-dependent apoptosis in HCC1937 (human TNBC), BT-474 (human HER2+/HR+), and 4T1 (mouse TNBC) cells. In contrast, in MDA-MB-468 (human TNBC) and MCF-7 (human HR+) cells, the cell death was induced via a non-apoptotic pathway. The in vivo efficacy of compound 19 was validated using a syngeneic orthotopic 4T1 model in BALB/c mice, resulting in significant reduction of 4T1 breast tumor growth upon intraperitoneal (i.p.) application of doses of 5 or 20 mg/kg. These findings highlight the potential of compound 19 as a promising scaffold for the development of new therapeutic agents for various types of breast cancer and a first structure-activity insight.
Publikation
Smolková, R.; Smolko, L.; Samoľová, E.; Morgan, I.; Rennert, R.; Kaluđerović, G. N.;Novel Zn(ii), Co(ii) and Cu(ii) diflunisalato complexes with neocuproine and their exceptional antiproliferative activity against cancer cell linesDalton Trans.5317595-17607(2024)DOI: 10.1039/d4dt01736f
Three novel complexes of deprotonated diflunisal (dif) with neocuproine (neo) were synthesized and characterized via elemental, spectral (UV-vis, FTIR, fluorescence, and mass spectrometry), and single-crystal X-ray diffraction analyses. Although the compounds shared a similar composition of [MCl(dif)(neo)], where M represents Zn(II) (1), Co(II) (2) and Cu(II) (3), only 1 and 2 were isostructural, while 3 differed in both the molecular and supramolecular structures. In all three complex molecules, the central atom is coordinated by two nitrogen atoms of neo in a bidentate chelate mode, and one chlorido ligand and dif is bonded in either a monodentate mode via one oxygen atom of the carboxylate in 1 and 2 or in a bidentate chelate mode via both carboxylate oxygen atoms in 3. All three compounds demonstrated remarkable antiproliferative activity against human prostate (PC-3), colon (HCT116) and breast (MDA-MB-468) cancer cell lines with IC50 values in the nanomolar range, with the lowest values observed in the case of PC-3 and MDA-MB-468 with 2 (20.0 nM) and 3 (31.1 nM), respectively. Moreover, complex 2, as the most active, was further investigated for its potential to induce perturbations in the cell cycle of PC-3 cells. The results indicated an induction of caspase-independent apoptosis. The interaction of the complexes with genomic DNA isolated from the respective cancer cell lines was evaluated for the intercalative mode, with binding strength correlated with the antiproliferative activity against PC-3 and MDA-MB-468 cancer cell lines.